drugset / Trial / NCT05387603
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
RandomizedParallel-groupOpen-labelTreatment
Summary
There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2026-10-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg | Oral |
| Subject | Lutetium Lu 177-Edotreotide | Peptide | 7500 mbq | Intravenous |